Current opinion in pulmonary medicine
-
Obstructive sleep apnea is a common disorder. Despite reports of its role as a risk factor for postoperative morbidity and mortality, only a few investigators have examined the optimal treatment of patients during this vulnerable period. Recognition of obstructive sleep apnea during conscious sedation or in the perioperative period is important to prevent the occurrence of adverse outcomes. This review discusses the influence of sedative, anesthetic, and analgesic agents and other factors during the perioperative period on patients with obstructive sleep apnea. The aim of this article is to emphasize the importance of recognizing and appropriately treating surgical patients with obstructive sleep apnea. ⋯ Obstructive sleep apnea places a significant proportion of surgical patients at increased risk of perioperative complications. Obstructive sleep apnea can be induced, unmasked, or exacerbated by the effects of sedative, analgesic, and anesthetic agents regardless of the site of surgery. The role of sleep apnea as a risk factor for development of postoperative complications needs greater emphasis. Increased awareness of the risk posed by an obstructed upper airway and appropriate management are important to optimize the perioperative care of patients with obstructive sleep apnea.
-
This review addresses the growing interest in the study of sleep during critical illness. ⋯ A more complete understanding of the etiopathogenesis of sleep derangements during mechanical ventilation may identify new interventions to help improve sleep, and possibly favorably influence short-term and long-term outcomes.
-
There has been much recent interest in the use of macrolide antibiotics as chronic suppressive therapy in patients with cystic fibrosis. Three recent randomized, placebo-controlled trials have been conducted. ⋯ Azithromycin has entered the therapeutic armamentarium for patients with cystic fibrosis who are chronically infected with Pseudomonas aeruginosa. Improved lung function, a reduction in pulmonary exacerbations and antibiotic use, and weight gain are potential benefits of this drug. Future studies should address the use of azithromycin in other cystic fibrosis patient populations, including those patients without chronic infection with P. aeruginosa, children younger than 6 years of age, and those infected with Burkholderia cepacia complex. The mechanism of action of macrolide antibiotics in cystic fibrosis remains unknown.
-
The purpose of this review is to summarize the recent approaches using mutation-specific therapy to correct the genetic defect according to the molecular mechanism by which the mutation causes the defects in cystic fibrosis transmembrane conductance regulator (CFTR). Premature stop mutations (class I mutations) account for 5 to 10% of the total mutant alleles in cystic fibrosis patients, and in certain subpopulations the incidence is much higher. ⋯ It is as yet unknown how much corrected mutant CFTR must reach the apical membrane to induce a clinically relevant beneficial effect. The future goal is to maximize the effect of stop-codon supressors on CFTR while minimizing side effects, but further studies must be performed to find a safer compound that may be administered in small children from the time of diagnosis.
-
Review Comparative Study
External validation and comparison of recently described prediction rules for suspected pulmonary embolism.
The assessment of pretest probability, allowing the categorization of patients clinically suspected of having pulmonary embolism in low, intermediate, and high clinical probability, is an essential step in contemporary diagnostic strategies because it permits limiting the number of additional diagnostic tests, especially invasive tests. Clinical probability can be evaluated implicitly or by prediction rules. Two prediction rules for pulmonary embolism have been described: the Canadian prediction rule (the Wells score) and the Geneva prediction rule. Their original descriptions were published in 2000 and 2001, respectively. These prediction rules need to be externally validated, and, ideally, outcome studies should demonstrate that patients may be safely treated on the basis of the assessment of the clinical probability they provide. Therefore, the purpose of this review is to discuss the external validation of these rules, because this particular point has been only recently achieved. ⋯ Studies comparing an empiric assessment with explicit assessment, such as the Wells simplified score or the Geneva score, have shown that the three tools show similar accuracy. External validation and use of both rules in prospective management studies have only recently been performed and have confirmed their validity. Some reports suggest that empiric assessment may be influenced by level of training. Objective prediction rules seems to be less influenced by experience and should be preferred by more junior doctors. The tool used for clinical probability assessment is probably less important than the principle of a careful clinical probability assessment in each patient with suspected pulmonary embolism.